Suppr超能文献

肥胖患者动脉高血压的管理。

Management of arterial hypertension in obese patients.

作者信息

Wenzel Ulrich O, Krebs Christian

机构信息

III Medizinische Klinik, Universitätsklinikum Hamburg Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany.

出版信息

Curr Hypertens Rep. 2007 Dec;9(6):491-7. doi: 10.1007/s11906-007-0090-7.

Abstract

Obesity prevalence is increasing. Obesity frequently coexists with-and can cause or worsen-arterial hypertension. However, no current guidelines provide specific recommendations. Antihypertensive drug treatment is indicated in most obese hypertensive patients, leading to the obvious question: what is the best drug treatment for this population? Some antihypertensive agents may have unwanted effects on the metabolic and hemodynamic abnormalities linking obesity and hypertension. Without adequate studies, recommendations for or against each class of antihypertensive agents are based on subjective criteria and pathophysiologic assumptions. Diuretics and beta-blockers have unwanted effects, whereas calcium antagonists are metabolically neutral, and angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers may increase insulin sensitivity. The renin-angiotensin system in adipose tissue has been implicated in arterial hypertension, and sodium retention is central to obesity-related hypertension. Therefore, an ACE inhibitor or diuretic should be considered as first-line antihypertensive drug therapy in obesity-hypertension.

摘要

肥胖症的患病率正在上升。肥胖症常与动脉高血压并存,并且可能导致动脉高血压或使其恶化。然而,目前尚无指南提供具体建议。大多数肥胖高血压患者都需要进行抗高血压药物治疗,这就引出了一个显而易见的问题:针对这一人群的最佳药物治疗方案是什么?一些抗高血压药物可能会对将肥胖与高血压联系起来的代谢和血流动力学异常产生不良影响。由于缺乏充分的研究,对于各类抗高血压药物的支持或反对建议是基于主观标准和病理生理假设的。利尿剂和β受体阻滞剂有不良影响,而钙拮抗剂对代谢无影响,血管紧张素转换酶(ACE)抑制剂和血管紧张素受体阻滞剂可能会提高胰岛素敏感性。脂肪组织中的肾素-血管紧张素系统与动脉高血压有关,钠潴留是肥胖相关高血压的核心问题。因此,ACE抑制剂或利尿剂应被视为肥胖高血压的一线抗高血压药物治疗。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验